Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy - Trial NCT05763706
Access comprehensive clinical trial information for NCT05763706 through Pure Global AI's free database. This phase not specified trial is sponsored by Jessa Hospital and is currently Recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 172 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)
Interventional
device
Sponsor & Location
Jessa Hospital
Timeline & Enrollment
N/A
Mar 27, 2023
Mar 15, 2030
Primary Outcome
Modified total neuropathy score (mTNS),Modified total neuropathy score (mTNS),Modified total neuropathy score (mTNS),Pain score,Pain score,Pain score,Mobility score,Mobility score,Mobility score
Summary
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the
 management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is
 that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality
 of life.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05763706
Device Trial